Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin P Dinney

Showing results (71-80 of 202) with videos related to

Pageof 21
Sort By:
Urology|March 18, 2008
Clinical model of cost of bladder cancer in the elderlyCatherine D Cooksley, Elenir B C Avritscher, H Barton Grossman, et al.
Urology|September 2, 2014
Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomyRobert S Svatek, Timothy N Clinton, Clark A Wilson, et al.
Urologic Oncology|January 9, 2025
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211Giuseppe Fallara, Federico Belladelli, Daniele Robesti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Matrix metalloproteinase polymorphisms are associated with bladder cancer invasivenessA Karim Kader, Jun Liu, Lina Shao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survivalDan Leibovici, H Barton Grossman, Colin P Dinney, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 1, 2010
Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancerJie Lin, Jianming Wang, Anthony J Greisinger, et al.
Cancer|August 24, 2012
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final resultsArlene O Siefker-Radtke, Colin P Dinney, Yu Shen, et al.
World Journal of Urology|June 12, 2021
Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care centerKelly K Bree, Patrick J Hensley, Nathan Brooks, et al.
BJU International|November 30, 2021
Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centreNiyati Lobo, Kelly K Bree, Patrick J Hensley, et al.
Plos One|June 16, 2012
Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-GuérinHua Wei, Ashish Kamat, Meng Chen, et al.
Pageof 21

Showing results (71-80 of 202) with videos related to

Sort By:
Pageof 21
Urology|March 18, 2008
Clinical model of cost of bladder cancer in the elderlyCatherine D Cooksley, Elenir B C Avritscher, H Barton Grossman, et al.
Urology|September 2, 2014
Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomyRobert S Svatek, Timothy N Clinton, Clark A Wilson, et al.
Urologic Oncology|January 9, 2025
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211Giuseppe Fallara, Federico Belladelli, Daniele Robesti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Matrix metalloproteinase polymorphisms are associated with bladder cancer invasivenessA Karim Kader, Jun Liu, Lina Shao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survivalDan Leibovici, H Barton Grossman, Colin P Dinney, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 1, 2010
Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancerJie Lin, Jianming Wang, Anthony J Greisinger, et al.
Cancer|August 24, 2012
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final resultsArlene O Siefker-Radtke, Colin P Dinney, Yu Shen, et al.
World Journal of Urology|June 12, 2021
Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care centerKelly K Bree, Patrick J Hensley, Nathan Brooks, et al.
BJU International|November 30, 2021
Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centreNiyati Lobo, Kelly K Bree, Patrick J Hensley, et al.
Plos One|June 16, 2012
Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-GuérinHua Wei, Ashish Kamat, Meng Chen, et al.
Pageof 21